Workflow
Junshi Biosciences(688180)
icon
Search documents
君实生物9月9日现1笔大宗交易 总成交金额4792万元 溢价率为-0.70%
Xin Lang Cai Jing· 2025-09-09 10:29
Group 1 - The stock of Junshi Biosciences rose by 1.54%, closing at 48.26 yuan, with a significant block trade of 1 million shares totaling 47.92 million yuan [1] - The first transaction occurred at a price of 47.92 yuan for 1 million shares, with a premium rate of -0.70%, involving the buyer from Founder Securities and the seller from CITIC Securities [1] - Over the past three months, the stock has seen a total of three block trades with a cumulative transaction amount of 143 million yuan, and in the last five trading days, it has increased by 4.30% with a net inflow of 62.25 million yuan from main funds [1]
君实生物股价涨5.11%,鹏华基金旗下1只基金重仓,持有12.16万股浮盈赚取29.56万元
Xin Lang Cai Jing· 2025-09-09 02:15
从基金十大重仓股角度 9月9日,君实生物涨5.11%,截至发稿,报49.96元/股,成交3.14亿元,换手率0.84%,总市值512.93亿 元。 资料显示,上海君实生物医药科技股份有限公司位于上海市浦东新区平家桥路100弄6号7幢16层,香港铜 锣湾希慎道33号利园1期19楼1918室,成立日期2012年12月27日,上市日期2020年7月15日,公司主营业 务涉及单克隆抗体药物和其他治疗型蛋白药物的研发与产业化,单克隆抗体药物研发的技术服务与技术 转让等。主营业务收入构成为:药品销售90.67%,技术许可及特许权使用收入8.74%,技术服务及其他 0.59%。 数据显示,鹏华基金旗下1只基金重仓君实生物。鹏华上证科创板生物医药ETF(588250)二季度持有 股数12.16万股,占基金净值比例为4.1%,位居第七大重仓股。根据测算,今日浮盈赚取约29.56万元。 鹏华上证科创板生物医药ETF(588250)成立日期2025年3月12日,最新规模1.01亿。成立以来收益 35.22%。 风险提示:市场有风险,投资需谨慎。本文为AI大模型自动发布,任何在本文出现的信息(包括但不 限于个股、评论、预测、图表、指 ...
港股异动 | 君实生物(01877)拉升逾9% JS005在治疗中重度斑块状银屑病Ⅲ期临床研究中取得阳性结果
智通财经网· 2025-09-09 02:13
Core Viewpoint - Junshi Biosciences (01877) experienced a significant stock increase of over 9%, with a current price of HKD 38.36 and a trading volume of HKD 173 million, following the positive results of its clinical trial for JS005, a monoclonal antibody targeting IL-17A in treating moderate to severe plaque psoriasis [1]. Group 1: Clinical Trial Results - The company announced that its product, JS005, achieved positive results in a pivotal Phase III clinical trial (Study No: JS005-005-III-PsO) for treating moderate to severe plaque psoriasis, meeting both primary and key secondary endpoints with statistical significance and clinical relevance [1]. - The trial demonstrated that JS005 significantly improved the psoriasis lesion area and severity compared to the placebo, with a notably higher proportion of participants achieving a sPGA score of 0 or 1 [1]. - The safety profile of JS005 was found to be good among participants with moderate to severe plaque psoriasis, and the results are planned to be presented at an upcoming international academic conference [1]. Group 2: Regulatory Plans - The company plans to submit a marketing authorization application for JS005 to regulatory authorities in the near future [1].
君实生物拉升逾9% JS005在治疗中重度斑块状银屑病Ⅲ期临床研究中取得阳性结果
Zhi Tong Cai Jing· 2025-09-09 02:08
君实生物(01877)拉升逾9%,截至发稿,涨8.36%,报38.36港元,成交额1.73亿港元。 据介绍,JS005是公司自主研发的特异性抗IL-17A单克隆抗体。截至本公告披露日,JS005此项多中心、 随机、双盲、平行、安慰剂对照的关键注册性Ⅲ期临床研究(研究编号:JS005-005-Ⅲ-PsO)已顺利完 成,并达到共同主要研究终点和关键次要终点。 研究结果显示,与安慰剂相比,JS005可显著改善参与者的银屑病皮损面积和严重程度,达到sPGA评分 为0或1的参与者比例显著优于安慰剂,并在中重度斑块状银屑病参与者中安全性良好,相关研究结果计 划在未来国际学术会议上予以公布。 消息面上,君实生物发布公告,近日,公司产品重组人源化抗IL-17A单克隆抗体(代号:JS005)在治疗 中重度斑块状银屑病的一项多中心、随机、双盲、平行、安慰剂对照的关键注册性Ⅲ期临床研究(研究 编号:JS005-005-III-PsO)中取得阳性结果,共同主要研究终点和关键次要终点均具有统计学显著性和临 床意义的改善。公司计划将于近期向监管部门递交该产品的上市许可申请。 ...
君实生物9月8日获融资买入9542.79万元,融资余额12.96亿元
Xin Lang Cai Jing· 2025-09-09 01:19
Group 1 - The core viewpoint of the news highlights the trading performance and financing activities of Junshi Biosciences, indicating a high level of financing and short-selling activity, which may suggest investor sentiment and market dynamics [1] - On September 8, Junshi Biosciences experienced a decline of 0.98% in stock price, with a trading volume of 867 million yuan. The net financing purchase on that day was 15.66 million yuan, with a total financing and securities lending balance of 1.307 billion yuan [1] - The financing balance of Junshi Biosciences reached 1.296 billion yuan, accounting for 3.56% of its market capitalization, which is above the 90th percentile level over the past year, indicating a high financing level [1] Group 2 - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 90.67% of its revenue coming from drug sales [2] - For the first half of 2025, Junshi Biosciences reported a revenue of 1.168 billion yuan, representing a year-on-year growth of 48.64%, while the net profit attributable to shareholders was -413 million yuan, showing a year-on-year increase of 36.01% [2] - As of June 30, 2025, the number of shareholders of Junshi Biosciences increased by 5.88% to 31,200, while the average circulating shares per person decreased by 5.56% to 24,543 shares [2] Group 3 - As of June 30, 2025, among the top ten circulating shareholders of Junshi Biosciences, the Huaxia SSE STAR 50 ETF held 29.7167 million shares, a decrease of 536,700 shares from the previous period, while the E Fund SSE STAR 50 ETF increased its holdings by 630,000 shares to 22.2132 million shares [3] - Hong Kong Central Clearing Limited ranked as the tenth largest circulating shareholder with 13.1291 million shares, a decrease of 186,650 shares compared to the previous period [3]
君实生物-U9月8日大宗交易成交4720.00万元
Group 1 - The core point of the article is the recent large transaction involving Junshi Biosciences (君实生物-U), which occurred on September 8, with a transaction volume of 1 million shares and a transaction amount of 47.2 million yuan [2] - The transaction price was 47.20 yuan, representing a discount of 0.69% compared to the closing price of the same day [2] - The buyer was from Founder Securities Co., Ltd., while the seller was from CITIC Securities Co., Ltd. [2] Group 2 - In the last three months, Junshi Biosciences has recorded a total of 2 large transactions, with a cumulative transaction amount of 94.86 million yuan [2] - On the same day, the closing price of Junshi Biosciences was 47.53 yuan, showing a decrease of 0.98%, with a daily turnover rate of 2.36% and a total transaction amount of 867 million yuan [2] - The net inflow of main funds for the day was 9.28 million yuan, and over the past five days, the stock has increased by 0.89% with a total net inflow of 8.70 million yuan [2] Group 3 - The latest margin financing balance for Junshi Biosciences is 1.28 billion yuan, which has decreased by 2.47 million yuan over the past five days, reflecting a decline of 0.19% [2]
君实生物今日大宗交易折价成交100万股,成交额4720万元
Xin Lang Cai Jing· 2025-09-08 09:37
Group 1 - On September 8, Junshi Biosciences executed a block trade of 1 million shares, with a transaction value of 47.2 million yuan, accounting for 5.16% of the total trading volume on that day [1][2] - The transaction price was 47.2 yuan per share, which represents a discount of 0.69% compared to the market closing price of 47.53 yuan [1]
君实生物跌0.98%,成交额8.67亿元,近5日主力净流入-252.62万
Xin Lang Cai Jing· 2025-09-08 07:45
Core Viewpoint - Junshi Biosciences aims to establish itself as a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization, focusing on quality and innovation [2][3]. Company Overview - Junshi Biosciences, founded on December 27, 2012, and listed on July 15, 2020, specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs [7]. - The company is headquartered in Shanghai, China, and operates in the biopharmaceutical sector, specifically in the development of innovative drugs [7]. Product Development - The company has developed a significant product portfolio, including the first domestically approved PD-1 monoclonal antibody, Toripalimab, which has received approval for 11 indications in mainland China and is also approved in multiple countries including the US and EU [2]. - Junshi is also advancing its pipeline with Tifcemalimab, the first anti-BTLA monoclonal antibody entering clinical development, currently undergoing two Phase III trials [2]. Vaccine Development - Junshi's subsidiary, JunTuo Biotech, is collaborating with research institutions to develop vaccines, including those for monkeypox and Zika, which are currently in preclinical development [3]. - A partnership has been established with Peking University and other institutions to jointly develop a recombinant protein vaccine for monkeypox [3]. Financial Performance - For the first half of 2025, Junshi reported revenue of 1.168 billion yuan, a year-on-year increase of 48.64%, while the net profit attributable to shareholders was -413 million yuan, reflecting a 36.01% increase in losses [8]. - As of June 30, 2025, the number of shareholders increased to 31,200, with an average of 24,543 shares held per shareholder, a decrease of 5.56% [8]. Market Activity - On September 8, 2023, Junshi's stock price decreased by 0.98%, with a trading volume of 867 million yuan and a market capitalization of 48.799 billion yuan [1]. - The stock has shown no clear trend in major fund inflows, with a net outflow of 7.31 million yuan on the same day [4][5].
君实生物:抗IL-17A单抗治疗Ⅲ期临床达到主要研究终点,将递交产品上市许可申请
Cai Jing Wang· 2025-09-08 05:15
Core Insights - Company Junshi Biosciences announced positive results from a Phase III clinical trial of its recombinant humanized anti-IL-17A monoclonal antibody (code: JS005) for the treatment of moderate to severe plaque psoriasis, achieving both primary and key secondary endpoints with statistical significance and clinical relevance [1][2] - The company plans to submit a marketing authorization application to regulatory authorities in the near future for JS005 [1] Group 1 - JS005 is a specific anti-IL-17A monoclonal antibody developed by the company, targeting IL-17A, a cytokine associated with autoimmune diseases such as psoriasis, rheumatoid arthritis, and ankylosing spondylitis [1] - The mechanism of JS005 involves high-affinity binding to IL-17A, selectively blocking its interaction with receptors IL-17RA/IL-17RC, thereby inhibiting downstream signaling pathways and the release of inflammatory factors [1] Group 2 - As of the announcement date, the Phase III clinical trial for JS005 in moderate to severe plaque psoriasis has met its primary and key secondary endpoints, while the Phase II clinical trial for active ankylosing spondylitis has completed primary endpoint visits and entered an extended treatment phase [2]
君实生物:上半年民得维实现全渠道覆盖,探索社区和县域市场医疗合作模式
Cai Jing Wang· 2025-09-08 05:05
Core Insights - The company is actively expanding sales channels for its commercialized products beyond Toripalimab, focusing on enhancing revenue generation [1][2] - The management has outlined a clear strategy for business development, emphasizing collaboration and resource integration [2] Group 1: Product Commercialization - Mindewei® (Dexamethasone Hydrochloride Tablets) received conditional approval from the National Medical Products Administration in January 2023 and has achieved full-channel coverage by mid-2025, partnering with major e-commerce platforms and pharmacies [1] - Junmaikang® (Adalimumab) has eight approved indications and is included in the national medical insurance directory, with promotion managed by Maiwei Biotech [1] - Junshida® (Ongokrezi Monoclonal Antibody) was approved in October 2024 with three approved indications, and its commercialization is being advanced by partner Bochuang Pharmaceuticals [1] Group 2: Business Development Strategy - The company's business development team is actively pursuing connections between its pipeline and domestic and international resources, engaging in in-depth research and communication on multiple potential collaboration directions [2] - The company maintains an open and proactive attitude towards various types of business cooperation and aims to accelerate pipeline research and development [2] - Regular reviews of the pipeline will be conducted to identify candidates with business development potential and share innovative results promptly [2]